Efficacy of Carbohydrate Loading in Diabetic Type 2 Patients Undergoing CABG Surgery on CPB
Launched by DAMASCUS UNIVERSITY · Apr 26, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how preoperative carbohydrate loading (giving patients carbohydrates before surgery) affects diabetic type 2 patients who are undergoing coronary artery bypass graft (CABG) surgery. The goal is to see if this approach can help improve recovery and surgical outcomes for these patients, as it has shown benefits for non-diabetic patients but hasn't been thoroughly tested in those with diabetes.
To participate in this trial, you need to be a diabetic type 2 patient scheduled for CABG surgery using a heart-lung machine. Unfortunately, if you have type 1 diabetes, are undergoing different types of heart surgery, or if any important data is missing, you won't be eligible to join. If you qualify, you can expect to be part of a study that aims to better understand how carbohydrate loading could help improve your surgery experience and outcomes. The trial is currently recruiting participants of all ages and genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All diabetic type 2 patients undergoing isolated on-pump coronary artery bypass surgery.
- Exclusion Criteria:
- • Missing data.
- • Patients outside the study period.
- • Patients undergoing other cardiac surgeries.
- • Patients diagnosed with type 1 diabetes mellitus.
About Damascus University
Damascus University, a prestigious institution located in Syria, is committed to advancing medical research and healthcare innovation through its clinical trial initiatives. With a focus on fostering collaboration between academia and clinical practice, the university aims to enhance the understanding of various medical conditions and improve patient outcomes. By leveraging its extensive network of researchers, healthcare professionals, and state-of-the-art facilities, Damascus University strives to contribute to the global body of knowledge in the medical field and support the development of effective therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Damascus, , Syrian Arab Republic
Patients applied
Trial Officials
Mohammad B Izzat, FRCS(CTh)
Study Director
Damascus University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported